Current
best practices and rationalistic perspectives in causation-based
prevention, early detection and multidisciplinary treatment
of breast and gastric cancer
|
EDITOR
- IN - CHIEF
Dimitrios
H. Roukos,
MD, PhD
 |
Leader,
Personalized Cancer Genomic Medicine, Biobank, Ioannina University |
|
Leader, Translational Research, European Network of Excellence (EUNE) for Gastric Cancer |
Ioannina University School of Medicine,
451 10 Ioannina , Greece.
T: +30 26510 07423, F: +30 26510 07094
E-mail: droukos@cc.uoi.gr
Biosketch profile |
|
SHORT CV
Dr. D. Roukos has graduated from Athens University School of Medicine, Greece. He underwent specialist training in surgery at the J.W.Goethe-University Hospital in Frankfurt a.M., Germany where received his Doctorate (Dr.med). He moved back to Greece and since 1990 works at the Ioannina University School of Medicine. |
RESEARCH – SCIENTIFIC ACTIVITY |
1983 - 2007 |
Traditional medicine based on reductionist biology, genetics, pathology and clinical research focused on components of a system of interest. Fields of interest: Gastric, breast, colorectal cancer. |
2008 - today |
NETWORKS MEDICINE: Systems biology & and cancer networks approach towards a next-generation of biomarkers and drugs based on beyond genome and cancer genome structure on functional regulatory networks.
From reductionist ‘classical” medicine to innovative networks medicine
|
| SCIENTIFIC INTERNATIONAL RECOGNITION |
Action |
No. |
Description |
Innovation |
4
|
• Networks medicine (2011) and Systems Medicine (2010) in Pharmacogenomics
• Chromatin, Epigenomics 2011; 3: 395-9.
• miRNAs as regulators of cancer networks. Exp Rev Med Dev. 2011;8(2):
123-6.
• Novel clinico-genome network modelling. Expert Rev Mol Diagn. 2010;
10(1):33-48.
• Next-generation sequencing and epigenome technologies. Expert Rev Med Devices. 2010 |
| Publications |
|
Pubmed 157, ISI web of Science 159, Scopus 180.
Recent total Impact Factors of papers in ISI journals. |
Citations/
H-factor |
~5000/
55 |
SCOPUS: 5000 cites (h=60); ISI: 4000 cites (h=55). |
Editorials |
60 |
Published and in press in journals* (*indexed in PubMed/ISI/Scopus). |
| e-Books Editor |
2 |
1. Advances in personalized cancer management (fsg) |
| |
|
2. Cancer genome heterogeneity, functional networks and gene dysfunction-based cancer therapy |
| |
|
|
| Key evaluator - Reviewer |
|
Large-scale research projects |
|
|
• European Commission FP7-Health (Innovation) Expert, 2011, 2012
• France (ANR) (New technologies); Experts meeting, Paris Sept & Dec 2011.
Reviewer in National and International research projects (UK,
Netherlands, Italy, Taiwan)
(10) and fast-track papers with
honorarium
(Lancet Oncol) (4) and reviewer in multiple journals (>100). |
Lectures |
>100 |
• International Conferences: President/Organizer, Invited speaker - consensus expert's panel (40), Chairman (15) and member of the Scientific Committee (17).
• Greek Conferences: Invited Speaker (35) |
Editorial Board |
20 |
Editor-in-Chief (2), Associate Editor (7), and Editorial Board member (11) in journals* |
|
|
|
|
